Entrectinib – ROZLYTREK® (USA)
According to the NCI website, Entrectinib is an orally bioavailable inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Check for active clinical trials using this agent. (NCI Thesaurus)
Indikationen/Anwendungsmöglichkeiten gemäss chemocare.com
- Metastatic non-small cell lung cancer (NSCLC) with ROS-1 positive tumors
- Solid tumors with neurotrophic tyrosine kinase (NTRK) gene fusion
More Information in English:
Link to MedlinePlus, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to National Cancer Institute
Wiki
Link to Physicians Desk Reference (PDR)
Link to European Medicines Agency (EMEA)
Info for Patients presented by Scott Hamilton from Chemocare.com